Unlock instant, AI-driven research and patent intelligence for your innovation.

Liver cancer-specific biomarker

A biomarker, liver cancer technology, applied in the fields of biomaterial analysis, biochemical equipment and methods, and microbial determination/inspection.

Pending Publication Date: 2021-03-26
给科生物研究室株式会社
View PDF3 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, most of them have meaning as prognostic factors, and when used alone, their accuracy is low, so they cannot be used for screening tests yet, and the early diagnosis of liver cancer is judged to have reached its limit

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Liver cancer-specific biomarker
  • Liver cancer-specific biomarker
  • Liver cancer-specific biomarker

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0061] Example 1. Screening of blood markers using the database

[0062] 1-1. Screening of liver cancer cell-specific markers

[0063] Blood samples (15 normal liver patient samples (Normal liver, NL); 20 chronic hepatitis patient samples (Chronic hepatitis, CH); 10 3 samples from patients with liver cirrhosis (Liver Cirrhosis, LC); 18 samples from patients with early-stage hepatocellular carcinoma (Early HCC, eHCC); and 45 samples from patients with advanced hepatocellular carcinoma (Advanced HCC, avHCC)) After extracting total RNA using TRIzol reagent, the sequencing library was prepared using RNA Library Prep Kit for Illumina (Cat#E7420L), and sequenced by Illumina HiSeq 2000 according to the standard method of Illumina Company. After using STAR and Gencode v.25 to map the entire transcriptome of the analyzed liver, the expression profiles were replaced by FPKM values, then Gencode v.25 was used to classify the genotypes, and SignalP 4.1 was used to derive 12654 signal p...

Embodiment 2

[0068] Example 2. ELISA analysis of selected markers for the first time

[0069] 2-1. Confirmation of marker expression profiles

[0070] Blood samples (135 samples from 16 normal liver patients (Normal liver, NL ); 65 samples from 13 patients with chronic hepatitis (Chronic hepatitis, CH); 103 samples from 15 patients with liver cirrhosis (LiverCirrhosis, LC); 227 samples from 35 patients with early-stage hepatocellular carcinoma (Early HCC , eHCC); and 241 samples from 24 patients with advanced hepatocellular carcinoma (Advanced HCC, avHCC)) ( Figure 7 ), the expression levels of the selected 10 marker genes ( Figures 8a-8b ).

[0071] As a result, in the case of CCNB2, an average of 0.02 ng / ml was measured in patients with normal liver (NL), 0.2029 ng / ml in patients with chronic hepatitis (CH), and 0.43 ng / ml in patients with cirrhosis (LC), Patients with early stage hepatocellular carcinoma (eHCC) exhibited 0.27 ng / ml, and patients with advanced hepatocellular carc...

Embodiment 3

[0075] Example 3. Verification of early cancer diagnostic markers HMMR, NXPH4, PITX1, THBS4 and UBE2T

[0076] 3-1. Confirmation of marker expression profiles

[0077] Blood samples (222 samples from 49 normal liver patients (Normal liver, NL ); 115 samples from 31 patients with chronic hepatitis (Chronic hepatitis, CH); 183 samples from 46 patients with liver cirrhosis (LiverCirrhosis, LC); 345 samples from 77 patients with early-stage hepatocellular carcinoma (Early HCC , eHCC); and 283 samples from 64 patients with advanced hepatocellular carcinoma (Advanced HCC, avHCC)) ( Figure 10 ), the expression levels of the selected 10 marker genes ( Figures 11a-11b ).

[0078] As a result, when the protein expression levels of the five markers were measured in the validation cohort, in the case of HMMR, by comparing the results of the normal group with each liver disease group among a total of 230 samples, it was shown that in addition to Except for the liver cirrhosis group...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to the use of genes whose expression varies specifically in hepatocellular carcinoma as biomarkers for the detection and diagnosis of hepatocellular carcinoma, wherein the biomarkers of the present invention, HMMR, NXPH4, PITX1, THBS4, and UBE2T, since they change their expression specifically in hepatocellular carcinoma, can be used as hepatocellular carcinoma-specific markers, and furthermore, these biomarkers can be used independently or in combination with AFP, or can be independently combined to make a more specific and accurate diagnosis of hepatocellular carcinoma.

Description

technical field [0001] The present invention relates to liver cancer-specific biomarkers, and in more detail, relates to a gene whose expression is specifically changed for hepatocellular carcinoma as a biomarker for detecting and diagnosing liver cancer cells. Background technique [0002] Among cancers, liver cancer is known as one of the deadliest cancers in the world, and it is reported that more than about 500,000 people die from liver cancer every year, especially in Asia and sub-Saharan Africa. Liver cancer can be roughly divided into primary liver cancer (hepatocellular carcinoma) caused by liver cells itself and metastatic liver cancer caused by cancer of other tissues metastasizing to the liver. Among them, more than 90% of liver cancers are primary liver cancer. [0003] Hepatocellular carcinoma (HCC) is the fifth most common tumor in the world, and half a million people die from liver cancer every year (Okuda 2000). Survival rates for patients with HCC have not...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6886G01N33/574
CPCC12Q1/6886C12Q2600/158G01N33/57438G01N2333/471G01N2800/60G01N2333/9015G01N2333/78G01N2333/705G01N2333/91074
Inventor 南硕祐张正元殷正于
Owner 给科生物研究室株式会社